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Abstract 
Equine herpesvirus type 5 (EHV5) is a ubiquitous, yet obscure pathogen in the horse population and is commonly 
associated with fatal equine multinodular pulmonary fibrosis (EMPF). To date, little is known about the precise patho-
genesis of EHV5. Here, we evaluated the dynamics of EHV5 infection in representative ex vivo and in vitro equine 
models, using immunofluorescence staining and virus titration. EHV5 was unable to infect epithelial cells lining the 
mucosa of nasal and tracheal explants. Similarly, primary equine respiratory epithelial cells (EREC) were not suscepti-
ble to EHV5 following inoculation at the apical or basolateral surfaces. Upon direct delivery of EHV5 particles to lung 
explants, few EHV5-positive cell clusters were observed at 72 hours post-inoculation (hpi). These EHV5-positive cells 
were identified as cytokeratin-positive alveolar cells. Next, we examined the potential of EHV5 to infect three distinct 
equine PBMC populations  (CD172a+ monocytes,  CD3+ T lymphocytes and Ig light  chain+ B lymphocytes). Mono-
cytes did not support EHV5 replication. In contrast, up to 10% of inoculated equine T and B lymphocytes synthetized 
intracellular viral antigens 24 hpi and 72 hpi, respectively. Still, the production of mature virus particles was hampered, 
as we did not observe an increase in extracellular virus titer. After reaching a peak, the percentage of infected T and 
B lymphocytes decayed, which was partly due to the onset of apoptosis, but not necrosis. Based on these findings, 
we propose a model for EHV5 pathogenesis in the horse. Uncovering EHV5 pathogenesis is the corner step to finally 
contain or even eradicate the virus.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
As a member of the Gammaherpesvirinae subfamily, 
equine herpesvirus type 5 (EHV5) is optimally adapted 
to its natural host, meaning that infected horses are 
mainly asymptomatic [1]. EHV5 is endemic in the horse 
population and plenty of horses shed the virus in nasal 
secretions and/or carry the virus in peripheral blood 
mononuclear cells (PBMC) or lymphoid organs. None-
theless, only a small fraction of them develop severe 
clinical symptoms [2–10]. The virus typically causes 
upper respiratory tract disease (e.g. pharyngitis) or kera-
toconjunctivitis accompanied with clinical signs such as 
nasal and ocular discharge, tachypnea, coughing, fever, 
enlarged lymph nodes, anorexia, poor body condition 
and depression [2, 3, 11–13]. Single case reports linked 
EHV5 to B cell lymphomas, T cell leukemia and derma-
titis [14–16]. However, the most dreadful complication 
of an EHV5 infection is the development of fatal equine 
multinodular pulmonary fibrosis (EMPF) [17]. EMPF is 
characterized by the presence of multiple fibrotic nod-
ules throughout the lungs. Histologically, marked inter-
stitial fibrosis with an “alveolar-like” architecture, lined 
by cuboidal epithelial cells and thickening of the alveolar 
walls is visible [2, 17, 18]. The high correlation between 
the presence of EMPF and EHV5 DNA suggests that the 
virus is involved in the development of lung fibrosis. This 
is corroborated by the findings of a study on a closely-
related gammaherpesvirus murine herpesvirus type 4 
(MuHV4). MuHV4 induces lung fibrosis in mice with a 
progressive deposition of interstitial collagen, increased 
transforming growth factor β and T helper 2 cytokine 
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expression and hyperplasia of type II pneumocytes [19]. 
Similarly in humans, the development of idiopathic 
pulmonary fibrosis has been linked to the gammaher-
pesvirus Epstein-Barr virus (EBV) [20, 21]. In addition, 
Williams et  al. [22] were able to experimentally induce 
lung fibrosis in horses upon direct delivery of virulent 
EHV5 strains into the lungs. However, the choice of viral 
strain, immunologic status of experimental animals and 
inoculation route may have favoured the outcome of dis-
ease. So far, the exact pathogenic role played by EHV5 in 
EMPF is unknown. The virus may be an etiologic agent or 
cofactor in the development of EMPF [2, 22].
Despite the large number of epidemiological studies, 
little is known about the exact pathogenesis of EHV5 
and many statements remain speculative. It is assumed 
that foals become infected through the upper respira-
tory tract around the age of 1–6  months [23]. Closely-
related gammaherpesviruses, such as human herpesvirus 
type 8 (HHV8), bovine herpesvirus type 4 (BoHV4) and 
MuHV4 commonly spread through sexual contact or 
intrauterine transmission. Still, the presence of EHV5 
in the equine reproductive tract has not been reported 
yet [24–26]. Following primary infection, EHV5 estab-
lishes latency to persist in its host. Viral DNA is com-
monly isolated from blood-derived PBMC (mainly T 
and B lymphocytes) of healthy horses, indicating that 
these leukocyte subpopulations are the latency reservoirs 
of EHV5 [9, 10, 23, 27]. However, the exact mechanism 
used by EHV5 to reach and infect these cells is unknown. 
Besides blood- and lymph node-derived PBMC, also 
alveolar macrophages were found to harbour the virus [2, 
17, 18, 22]. However, whether this observation was due 
to a direct viral infection or a consequence of phagocy-
tosis remains speculative. In the lungs of horses suffering 
from EMPF, EHV5 antigens were additionally localized in 
alveolar pneumocytes and interstitial fibroblasts, indicat-
ing that the virus can infect these cell types [22].
Although EHV5 is an old pathogen, it only recently 
attracted the attention of clinicians, horse  owners and 
researchers due to its association with EMPF. Effective 
therapies are lacking due to the limited knowledge on 
EHV5 pathogenesis in the horse. Therefore, our study 
aimed to uncover some of the first key steps herein.
Materials and methods
Virus
The equine herpesvirus type 5 (EHV5) KB-P48 strain was 
kindly provided by Dr K. Borchers and originates from 
the blood taken of a captive Przewalski’s wild horse [28]. 
The horse had high immunoperoxidase monolayer assay 
(IPMA) and virus neutralizing (VN) anti-EHV5 antibody 
titers, but showed no clinical symptoms. The virus was 
propagated on rabbit kidney (RK13) cells and used at the 
 6th passage.
The alphaherpesvirus equine herpesvirus type 1 
(EHV1) is known to infect both leukocytes (e.g.  CD173a+ 
monocytic cells, T and B lymphocytes) and the res-
piratory epithelium of the horse [29–31]. Therefore, the 
EHV1 strain 03P37 was used as a positive control dur-
ing our viral infection assays. The 03P37 strain originates 
from the blood taken of a paralytic horse during an out-
break in 2003 [32]. The virus was propagated on RK13 
cells and used at the  6th passage.
Tissue collection and processing
The nasal septa, tracheae and lungs from three differ-
ent healthy horses were collected at the slaughterhouse. 
Standardbred and warmblood mares or geldings of 3 to 
15  years of age were selected. Tissues were transported 
in PBS with calcium and magnesium  (PBS+Ca+Mg), sup-
plemented with 0.1  mg/mL gentamicin (ThermoFisher 
Scientific, Waltham, MA, USA), 0.1  mg/mL kanamycin 
(Sigma-Aldrich, St. Louis, MO, USA), 100  U/mL peni-
cillin, 0.1  mg/mL streptomycin (ThermoFisher Scien-
tific) and 0.25  μg/mL amphotericin B (ThermoFisher 
Scientific).
Respiratory mucosal explant isolation and cultivation
Nasal and tracheal mucosal explants were prepared and 
cultivated as previously described [33, 34]. Lung explants 
were obtained following a technique described for pigs, 
with minor adaptations [35]. Briefly, lung tissue was first 
cut up in cubes of approximately 1  cm × 1  cm × 5  cm 
(W × H × L). These cubes were then transferred to a 
20 mL syringe containing 5 mL of 4% agarose (low tem-
perature gelling; Sigma-Aldrich), diluted in PBS. After 
filling the syringe with 5 mL of additional agarose, it was 
transferred to 4  °C until the agarose solidified (15 min). 
The tip of the syringe was cut off, before gently push-
ing the plunger and thereby moving the embedded lung 
tissue out of the barrel. Using a cryotome blade, thin 
lung tissues slices of 1  mm were cut and transferred to 
a petridish. Here, tissues were thoroughly washed to 
remove excess agarose and finally trimmed to a surface 
of approximately 25  mm2. Lung explants were trans-
ferred to 6-well plates, submerged in serum-free medium 
(DMEM/RPMI [ThermoFisher Scientific], supplemented 
with 0.1  mg/mL gentamicin, 100 U/mL penicillin, 
0.1 mg/mL streptomycin, and 0.25 μg/mL amphotericin 
B) and cultivated at 37 °C and 5%  CO2.
EREC isolation and cultivation
Primary equine respiratory epithelial cells (EREC) were 
isolated and cultured as described previously [34, 36].
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Isolation of equine monocytes, T and B lymphocytes
Equine PBMC were isolated as described previously [31]. 
The collection of blood was approved by the ethical com-
mittee of Ghent University (EC2017/118). Ten hours 
post seeding,  CD172a+ monocytic cells had adhered to 
the plastic (purity > 90%, as assessed by flow cytometry 
[31]) and non-adherent cells consisted of two dominant 
leukocyte populations: T and B lymphocytes. Following 
removal of non-adherent cells, equine  CD172a+ mono-
cytes were further maintained in RPMI supplemented 
with 5% fetal calf serum (FCS) and antibiotics. Equine 
T lymphocytes were separated from B lymphocytes 
by negative selection magnetic-activated cell sorting 
(MACS). In summary, 5 × 107 cells were incubated with 
a mouse anti-horse pan B lymphocyte antibody (clone 
CVS36, directed against the equine Ig light chains; Bio-
Rad, Oxford, UK), diluted in PBS with 10% negative 
goat serum (NGS) for 1 h at 4  °C. Cells were washed in 
ice-cold elution buffer (PBS + 2  mM EDTA + 2% FCS) 
and re-suspended in elution buffer, containing 100 µL 
rat anti-mouse IgG micro-beads (MACS Miltenyi Bio-
tec, Cologne, Germany) for 1 h at 4  °C. Next, cells were 
washed in elution buffer before transferring them onto 
a LS column (MACS Miltenyi Biotec). The cell-frac-
tion that went through the column was collected and 
contained over 95% positive  CD3+ T lymphocytes, as 
assessed by flow cytometry after indirect immunofluo-
rescence staining with a mouse anti-equine CD3 mono-
clonal antibody (clone UC_F6G; California University, 
Davis, Additional file  1A). The remaining cell-fraction 
contained the Ig light  chain+ B lymphocytes, as assessed 
by flow cytometry after indirect immunofluorescence 
staining with a mouse anti-pan B lymphocyte antibody 
(clone CVS36; Additional file 1B). Finally, equine T and 
B lymphocytes were counted using a Bürker counting 
chamber and seeded in RPMI supplemented with 5% 
FCS, 1% MEM non-essential amino-acids, 1% sodium 
pyruvate, 4 U/mL interleukin-2 and antibiotics.
Viral infection assays
Respiratory mucosal explants
Explants were cultured 24 h for adaptation before thor-
oughly washing and transferring them to a clean 24-well 
plate, as previously published [33]. While lung explants 
were left untreated, nasal and tracheal explants were 
incubated with 8 mM EGTA or  PBS+Ca+Mg (control) for 
1 h at 37 °C to dissociate intercellular junctions [34]. Fol-
lowing a thorough washing step, nasal, tracheal and lung 
explants were subsequently exposed to medium alone 
(mock), the KB-P48 EHV5 strain  (106.5  TCID50) or the 
03P37 EHV1 strain  (106.5  TCID50, positive control) for 
1 h at 37 °C. Explants were then washed 3 times in PBS 
to remove unbound virus particles. Finally, explants were 
placed back onto their gauzes and serum-free medium 
was added. At corresponding time points, explants were 
placed in methylcellulose-filled plastic tubes and snap-
frozen at −80 °C until further processing.
EREC
We recently described a protocol for apical versus baso-
lateral infection of EREC by EHV1 in a transwell system 
[34]. Cells were grown to confluency and the trans-epi-
thelial electrical resistance (TEER) was measured daily 
until a steady TEER of ~ 500–700 Ω × cm−2 was attained. 
The apical surface of EREC was then treated with 8 mM 
EGTA or  PBS+Ca+Mg for 30  min at 37  °C to dissociate 
the intercellular junctions. Following a washing step in 
PBS, cells were exposed to medium alone (mock), 100 μL 
KB-P48 EHV5 strain (MOI of 1) or 03P37 EHV1 strain 
(MOI of 1) at either the apical or the inverted basolat-
eral surface for 1  h at 37  °C. Non-adsorbed virus parti-
cles were removed by washing the EREC three times 
with DMEM/F12. Fresh EREC-medium was added to the 
platewells and cells were further incubated at the air–liq-
uid interface. At corresponding time points, cells were 
fixed in methanol for 20 min at −20 °C and stored dry at 
−20 °C until further processing.
Equine monocytes, T and B lymphocytes
Monocytes, grown on cover slips, were mock-inoculated 
or inoculated with either EHV5 (MOI 1 or 10) or EHV1 
(MOI 1; positive control) in 200 µL monocyte medium 
for 1 h at 37 °C. Afterwards, the cells were gently washed 
twice to remove the inoculum and further incubated with 
fresh medium. At 6, 24, 48, 72 and 96 hpi (hours post-
inoculation), cell supernatant was collected, and cells 
were fixed in methanol for 20 min at −20 °C and stored 
dry at −20 °C until further processing.
T and B lymphocytes were inoculated at a concentra-
tion of 2.5 × 106 cells/mL with EHV5 (MOI 1 or 10) or 
EHV1 (MOI 1) diluted in lymphocyte medium for 1  h 
at 37  °C. The inoculum was removed by 2 centrifuga-
tion steps at 300 × g and cells were further incubated in 
24-well plates with fresh medium. At 6, 24, 48, 72 and 96 
hpi, cells were pelleted by centrifugation at 300  g. The 
supernatant, containing free virus particles, was collected 
and cells were fixed in 1% paraformaldehyde (PFA) for 
10  min at room temperature (RT) and finally stored in 
PBS at 4 °C until further processing.
Polyclonal anti‑EHV5 antibody
The polyclonal horse anti-EHV5 antibody originates 
from blood taken of a Shetland pony stallion (Sultan) 
intended for routine diagnostic serological examination. 
The pony was kept in a premise, where one of the five 
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horses (Haflinger breed) showed signs of nasal discharge 
and dullness and was diagnosed with EHV5 by PCR on 
a nasal swab. The affected horse was isolated from the 
herd and all horses (the Haflinger and four Shetland 
ponies) were screened for the presence of EHV5-specific 
antibodies, regarding further isolation management. The 
amount of anti-EHV5 specific IPMA and VN antibod-
ies was semi-quantitatively determined on RK13 cells 
using an IPMA  (102  TCID50 KB-P48) or a seroneutrali-
zation test, respectively. Antibodies against EHV5 were 
present in the sera of all five horses and the titer ranged 
from 2 to > 256 (Sultan) for VN antibodies and from 2560 
to 40,960 (Sultan) for IPMA antibodies. The antibodies 
from Sultan’s serum were then purified and biotinylated, 
similarly to the polyclonal horse anti-EHV1 antibody 
previously made in our lab [37]. As shown in Additional 
file  2, left panels, the positive signal in EHV5-infected 
RK13 cells following both immunofluorescence (A) and 
immunocytological (B) staining with the biotinylated 
Sultan antibody (1:20) and subsequent incubation with 
streptavidin-FITC® or streptavidin-HRP, respectively, 
confirmed its suitability in further staining experiments. 
The biotinylated polyclonal horse anti-EHV1 antibody 
mixture did not contain anti-EHV5 antibodies and was 
used as a negative control (Additional file 2, right panels).
Immunofluorescence staining and confocal microscopy
Explants
Sixteen μm thick cryosections of equine nasal, tracheal 
and lung explants were cut using a cryostat at −20  °C 
and loaded onto 3-aminopropyltriethoxysilane-coated 
(Sigma-Aldrich) glass slides. Slides were then fixed in 4% 
PFA for 15 min and subsequently permeabilized in 0.1% 
Triton-X 100 diluted in PBS. Non-specific binding sites 
(e.g. equine IgG receptor) were first blocked by 45  min 
incubation with 10% negative horse serum, obtained 
during a previous in  vivo study [38], diluted in PBS at 
37 °C. To label EHV5 and EHV1 proteins, the polyclonal 
biotinylated horse anti-EHV5 antibody (Sultan; 1:20) 
or polyclonal biotinylated horse anti-EHV1 antibody, 
respectively, was used for 1 h at 37 °C, followed by incu-
bation with streptavidin-FITC® for 1  h at 37  °C. Nuclei 
were detected by staining with Hoechst 33342 (Ther-
moFisher Scientific). Transwell membranes were excised 
from the culture inserts and mounted on glass slides 
using glycerol-DABCO. The number of viral plaques and/
or single infected cells was evaluated on 100 consecutive 
cryosections, using confocal microscopy.
A double immunofluorescence staining of lung explant 
cryosections was performed to identify EHV5-positive 
cells as cytokeratin-positive. For this, cryosections were 
incubated for 1  h with the polyclonal biotinylated anti-
EHV5 antibody (1:20), together with the monoclonal 
mouse anti-pan cytokeratin antibody (clone AE1/AE3; 
Agilent, Santa Clara, USA; 1:100). After a washing step, 
cryosections were incubated with streptavidin-FITC® 
and a goat anti-mouse IgG Texas  Red®-conjugated anti-
body (ThermoFisher Scientific). Nuclei were detected by 
staining with Hoechst 33342.
EREC
Methanol-fixed EREC were directly stained in the tran-
swells, as described above. The complete EREC mon-
olayer was analysed using a Leica (TCS SPE) confocal 
microscope. As a negative control, mock-inoculated cells 
were stained following the above protocols. The poly-
clonal horse anti-EHV1 antibody was included as isotype 
control antibody [37].
Equine monocytes, T and B lymphocytes
Methanol-fixed monocytes, grown on cover slips, were 
stained directly in the wells. PFA-fixed lymphocytes were 
cytospinned onto 3-aminopropyltriethoxysilane-coated 
(Sigma-Aldrich) glass slides and subsequently permea-
bilized in 0.1% Triton-X 100 diluted in PBS. Immuno-
fluorescence staining further proceeded as described 
previously. Slides were mounted with glycerol-DABCO 
and analysed using confocal microscopy. The percent-
age of viral antigen-positive cells was calculated based on 
300 cells counted in 5 distinct fields. In EHV5-infected 
lymphocytes, the percentage of cells showing DNA 
fragmentation due to EHV5 infection was additionally 
determined.
Cell death analysis
The percentage of mock- or EHV5-inoculated cells show-
ing signs of apoptosis (annexin V-positive) or necrosis 
(propidium iodide positive) was determined 72 hpi, using 
the “Dead Cell Apoptosis Kit” from ThermoFisher Scien-
tific (V13241). Live cells were incubated with the appro-
priate reagents following the manufacturer’s guidelines. 
Next, cells were fixed in 1% PFA and stained for EHV5 
antigens, as described above. The percentage of apop-
totic or necrotic cells was calculated based on 300 cells 
counted in 5 distinct fields using confocal microscopy.
Virus titration
Cell and explant supernatants were collected at various 
time points and stored at −80  °C until titration. EHV1 
and EHV5 titrations were conducted on RK13 cells, 
which were incubated at 37  °C for 7  days. EHV1 titers 
were determined based on cytopathogenic effect. EHV5 
titers were determined based on EHV5-immunocytolog-
ical staining. Briefly, RK13 cells were washed in PBS, air-
dried at 37 °C for 1 h and frozen at −20 °C for a minimum 
of 2 h. After thawing, cells were fixed in 4% PFA at 4 °C 
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for 15  min. Non-specific binding sites were blocked by 
incubating the cells with a mixture of tris-buffered saline 
(TBS), supplemented with 5% NGS for 20 min at 37  °C. 
EHV5-positive cells were stained with the anti-EHV5 
serum  (Sultan), diluted 1:1000 in TBS with 2% NGS. 
After washing, a goat anti-horse IgG-peroxidase (Jack-
son ImmunoResearch, Cambridgeshire, UK) was added 
in TBS. For detection, a 5% aminoethyl carbazole (AEC) 
solution, supplemented with 0.025%  H2O2 was added 
to the wells for 10 min at 37 °C. The enzymatic reaction 
was stopped by washing the cells in PBS. All titers were 
expressed as  TCID50.
Statistical analyses
Significant differences (P < 0.05) between different time 
points or different MOI were identified by analysis of 
variances (ANOVA) followed by Tukey’s post hoc test. 
If homoscedasticity of the variables was not met as 
assessed by Levene’s test, the data were log-transformed 
prior to ANOVA. Normality of the residuals was veri-
fied by the use of the Shapiro–Wilk test. If the variables 
remained heteroscedastic or normality was not met after 
log-transformation, a Kruskal–Wallis’ test, followed by 
a Mann–Whitney’s post hoc test were performed. Sig-
nificant differences in the percentage of apoptotic cells 
between mock or EHV5 inoculations were identified by 
a Student’s t test. All analyses were conducted in IBM 
SPSS Statistics for Windows, version 25.0 (IBM Corp, 
Armonck, NY, USA).
Results
EHV5 infects lung alveolar cells but not the equine ciliated 
respiratory epithelium lining the nasal septum and trachea
To date, it is unclear how exactly EHV5 establishes a life-
long infection in new hosts. The virus is delivered to the 
respiratory tract through inhalation and somehow finds 
its way to latency reservoirs (PBMC). Here, we exam-
ined whether EHV5 primarily infects equine respiratory 
epithelial cells using nasal and tracheal mucosal explant 
models and primary EREC. In addition, we examined 
whether EHV5 is able to infect cells within lung explants 
upon direct delivery.
Explants
Over the time course of the experiment  (24, 48 and  72 
hpi), EHV5-infected cells were not detected in the res-
piratory epithelium of nasal and tracheal mucosal 
explants. In contrast,  at 24 hpi, we counted an average 
of 3 ± 3 and 32 ± 15 EHV1 plaques in 8  mm2 respira-
tory epithelium of nasal and tracheal mucosal explants, 
respectively. As EHV1 infection is known to be enhanced 
upon disruption of epithelial integrity [34], nasal and tra-
cheal mucosal explants were treated with EGTA prior to 
inoculation with EHV5. Despite the EGTA treatment, 
EHV5-infected cells were not found in the respiratory 
epithelium of these explants. Finally, EHV1-positive leu-
kocytes were observed beneath the basement membrane 
24 hpi. However, EHV5-positive leukocytes were absent 
in the EHV5-inoculated nasal and tracheal mucosal 
explants at all time points.
In lung explants, however, a small amount (22 ± 9) of 
EHV5-infected cells was present in a volume of 8  mm3 
lung tissue at 72  hpi. EHV5-positive cells were usually 
found in a cell cluster of approximately 4 ± 2 EHV5-pos-
itive cells per cluster. Double immunofluorescence stain-
ing for EHV5 antigens and cytokeratin confirmed that 
these infected cell clusters were of epithelial origins. Rep-
resentative confocal images are given in Figure 1.
Nasal, tracheal and lung explants did not produce 
detectable progeny EHV5 particles 72 hpi, as viral titers 
in the supernatant remained below 1  log10TCID50/
mL. The supernatant of nasal and tracheal mucosal 
explants 24 hpi contained an EHV1 titer of 2.4 ± 0.9 and 
2.5 ± 0.5  log10TCID50/mL, respectively.
EREC
EHV1 formed 1 ± 1 and 55 ± 26 viral plaques in 3 × 104 
EREC 10 hpi following inoculation at the apical or baso-
lateral surfaces, respectively. In contrast, none of the 
cells were EHV5-positive 96  h following inoculation at 
both surfaces. Similarly as observed in nasal and tracheal 
explants, disruption of EREC integrity with EGTA prior 
to inoculation did not overcome the restriction to EHV5 
infection of the cells.
EHV5 does not replicate in equine monocytic cells 
but induces a lytic infection in equine T and B lymphocytes 
in vitro
As the equine ciliated respiratory epithelium did not sup-
port EHV5 growth, we hypothesized that EHV5 directly 
infects PBMC. In comparison, the human gammaher-
pesvirus Epstein-Barr virus (EBV) is able to synthetize 
viral proteins and produce a lytic infection in human B 
lymphoblasts [39]. Therefore, we examined the ability of 
EHV5 to infect and replicate in equine PBMC. The kinet-
ics of viral protein expression and virus production in 
equine  CD3+ T lymphocytes, Ig light  chain+ B lympho-
cytes and  CD172a+ monocytes was evaluated by confo-
cal microscopy and virus titration on cell supernatant, 
respectively. Parallel mock inoculations confirmed the 
absence of EHV5-positive T lymphocytes, B lymphocytes 
and monocytes in the blood donor-derived PBMC.
T lymphocytes
In EHV5-inoculated T lymphocytes (MOI of 1), 1 ± 1% of 
the cells started to express viral proteins in the cytoplasm 
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at 6 hpi, as shown in Figure  2, left graph. This percent-
age slightly, but not significantly increased over time to 
2 ± 2% at 48 hpi and declined again to 1 ± 1% at 96 hpi. 
Increasing the MOI 10 times rapidly and significantly 
(P < 0.05) increased the percentage of infected cells to 
6 ± 3% at 6  hpi and 9 ± 4% at 24  hpi. Starting from this 
time point, the percentage of EHV5-infected T lympho-
cytes declined gradually to 3 ± 1.5% at 96 hpi. Represent-
ative confocal images are shown in the upper panel of 
Figure 2. EHV1 antigens were visible in 1 ± 0.3% equine T 
lymphocytes 24 hpi.
No significant increase in extracellular EHV5 titer was 
observed over the course of the experiment (Figure  2, 
right graph).
B lymphocytes
EHV5 inoculation of B lymphocytes at a MOI of 1 
resulted in an average of 1 ± 0.5% EHV5-positive cells 
6 hpi (Figure  3, left graph). This percentage increased 
over time to a peak of 3.5 ± 1% at 72 hpi, which was sig-
nificantly (P < 0.05) different from the percentages at 6, 
24 and 48 hpi. At 96 hpi, only 2 ± 1% of the inoculated B 
lymphocytes remained EHV5-positive. Again, increas-
ing the MOI to 10 resulted in a significant (P < 0.05) 
increase in cells expressing EHV5 proteins already at 
6 hpi (3 ± 2%). This percentage further increased in a 
time-dependent manner to 10 ± 4% at 72 hpi. Similarly 
as to EHV5-inoculated T lymphocytes, the percentage 
of EHV5-positive inoculated B lymphocytes decreased 
again at 96 hpi (5.5 ± 2%). Representative confocal 
images are shown in the upper panel of Figure  3. We 
observed 0.5 ± 0.2% EHV1-positive equine B lympho-
cytes 24 hpi.
No significant increase in extracellular EHV5 titer 
was observed over the course of the experiment (Fig-
ure 3, right graph).
Monocytes
EHV5 proteins were not detected in EHV5-inocu-
lated equine monocytes throughout the course of the 
Figure 1 EHV5 antigen expression 72 hpi in localized cell clusters within EHV5-inoculated lung explants. In the upper panel, cryosections 
were stained for EHV5 antigens (Sultan; green) and cell nuclei (Hoechst 33342; blue). In the lower panel, cryosections were simultaneously stained 
for EHV5 antigens (Sultan; green), cytokeratin (AE1/AE3; red) and cell nuclei (Hoechst 33342; blue). The scale bars represent 50 µm.
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experiment. In contrast, EHV1 antigens were expressed 
in 3.7 ± 1.4% of the inoculated monocytes 24 hpi.
EHV5 lytic infection causes nuclear fragmentation 
and apoptosis in equine T and B lymphocytes
It is known that EBV induces DNA fragmentation during 
lytic infection of human B lymphoblasts [39]. This DNA 
fragmentation contributes to the cytopathic effect of EBV 
and eventually ends in cell death. As EHV5 was able to 
induce a lytic replication in equine T and B lymphocytes, 
we analysed whether cell nuclear morphology changed 
upon infection using Hoechst 33342. The fluorescent 
dye Hoechst 33342 binds to the minor groove of double-
stranded DNA and can be used in immunofluorescence 
staining to identify chromatin condensation and nuclear 
fragmentation [40]. As nuclear fragmentation preludes 
cell death, we additionally analysed the percentage of 
cells showing signs of apoptosis (annexin V-positive) or 
necrosis (propidium iodide-positive) [41]. Apoptosis is a 
tightly regulated form of cell death and can be recognized 
by the binding of annexin V to phosphatidyl serine on the 
cell surface [42]. In contrast, propridium iodide can pen-
etrate the plasma membrane of necrotic cells and subse-
quently binds to nucleic acids.
Nuclear fragmentation
Starting from 6 hpi, we observed that EHV5 viral proteins 
co-localized with the nucleus of approximately 0.5 ± 0.5% 
of the EHV5-inoculated (MOI 10) T lymphocytes (Fig-
ure  4A) and 1 ± 1% of EHV5-inoculated (MOI 10) B 
lymphocytes (Figure  4B). Interestingly, all of these cells 
exhibited a translucent and/or punctuated Hoechst sig-
nal, as shown in the right panels of Figure 4A and B. The 
number of EHV5-positive T lymphocytes showing signs 
of nuclear fragmentation significantly (P < 0.05) increased 
to 3 ± 1% at 48 hpi and remained stable starting from this 
time point. The number of EHV5-positive B lympho-
cytes showing signs of nuclear fragmentation steadily 
increased in a time-dependent manner to 4.5 ± 1.5% at 
96 hpi. In contrast, less than 1% of mock-inoculated cells 
showed signs of nuclear fragmentation throughout the 
course of the experiment.
Figure 2 Expression of EHV5 antigens in EHV5-inoculated (MOI 1 or 10) T lymphocytes. At indicated time points, supernatant was collected 
for virus titration and cells were fixed and immunofluorescently stained for EHV5 antigens. Upper panel; representative confocal images of EHV5 
antigen expression (Sultan; green) in T lymphocytes. Cell nuclei were counterstained with Hoechst 33342 (blue). The scale bar represents 5 µm. 
Lower left panel; the percentage of EHV5-positive cells was calculated based on 300 cells counted in 5 distinct field. Lower right panel; the virus titer 
was determined in supernatant on RK13 cells. Data are represented as mean ± SD and asterisks indicate significant differences (*P < 0.05) between 
MOI 1 and 10. Experiments were performed on cells from 3 individual horses.
Page 8 of 14Van Cleemput et al. Vet Res           (2019) 50:13 
Cell death analysis
As shown in Figure  5, the percentage of apoptotic cells 
was significantly (P < 0.001) higher in EHV5-inoculated T 
lymphocytes (6.5 ± 1.5%) and B lymphocytes (11.5 ± 3%) 
72 hpi, compared to mock-inoculated T lymphocytes 
(4 ± 1.5%) and B lymphocytes (8 ± 2%), respectively. 
Simultaneously staining apoptosis (annexin V) and EHV5 
antigens confirmed their co-localisation in both T and B 
lymphocytes, as illustrated in the right panels of Figure 5.
No significant difference was found in the percentage 
of necrotic cells between EHV5- and mock-inoculated T 
and B lymphocytes at 72 hpi.
Discussion
The present study aimed at uncovering some of the first 
crucial steps in EHV5 pathogenesis, starting with the 
identification of susceptible target cells. For this, we 
first examined whether EHV5 can replicate in epithe-
lial cells lining the horse’s respiratory tract. Next, we 
evaluated EHV5 replication kinetics in different PBMC 
subpopulations, as PBMC are the presumable viral 
latency reservoirs.
Following direct delivery of EHV5 to equine nasal sep-
tum or tracheal mucosal explants, viral protein expres-
sion was not detected in respiratory epithelial cells or in 
single patrolling immune cells. These findings were cor-
roborated in primary equine respiratory epithelial cells 
(EREC), in which no EHV5-positive cells were found 
following inoculation at both the apical or basolateral 
surface. In comparison, human epithelial cells are diffi-
cult to infect in vitro with the human gammaherpesvirus 
Epstein–Barr virus (EBV) [43]. However, the virus is able 
to efficiently infect epithelial cells following EBV propa-
gation in B lymphocytes [44]. On the contrary, epithe-
lial-cell derived virus particles can infect B lymphocytes 
more efficiently. This state-of-the-art alternating cell tro-
pism is facilitated through the degradation of viral gp42 
by MHC II trafficking in B lymphocytes, thereby liber-
ating gH/gL from the gp42/gH/gL complex. It was pro-
posed that free gH/gL complexes are necessary for the 
interaction between the virion and epithelial cells. These 
Figure 3 Expression of EHV5 antigens in EHV5-inoculated (MOI 1 or 10) B lymphocytes. At indicated time points, supernatant was collected 
for virus titration and cells were fixed and immunofluorescently stained for EHV5 antigens. Representative confocal images of EHV5 antigen 
expression (Sultan; green) in B lymphocytes. Cell nuclei were counterstained with Hoechst 33342 (blue). The scale bar represents 5 µm (upper 
panel). The percentage of EHV5-positive cells was calculated based on 300 cells counted in 5 distinct fields (lower left panel). The virus titer was 
determined in supernatant on RK13 cells (lower right panel). Data are represented as mean ± SD and asterisks indicate significant differences 
(*P < 0.05) between MOI 1 and 10. Experiments were performed on cells from 3 individual horses.
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observations may be in line with our data, as the epithe-
lial cell-derived stock of EHV5 could efficiently infect 
equine T and B lymphocytes, but was unable to infect the 
ciliated respiratory epithelium. Interestingly, a few alveo-
lar cells became EHV5-positive following inoculation of 
equine lung explants. In an in vivo study from Williams 
et al. [22], EHV5 antigens were also detected in alveolar 
epithelial cells upon direct delivery of virus particles to 
the lungs. In addition, several studies already reported 
the presence of EHV5 DNA in equine lung tissues [45–
47]. However, care must be taken by extrapolating these 
results to the real in vivo situation, as it is highly unlikely 
that free virus particles can directly access the lungs upon 
inhalation in healthy horses. Indeed, most viruses that 
overcome the nasal filter end up in the trachea and are 
disposed by the mucociliary escalator [48, 49].
Next, we demonstrated that the percentage of EHV5-
positive T and B lymphocytes increased over time upon 
in vitro inoculation, reaching a peak at 24 hpi and 72 hpi, 
respectively, and then declined. This decay might indi-
cate that infection was cleared. For example, apoptosis or 
controlled cell destruction can act as an innate response 
to counteract viral infection. Indeed, apoptosis prevents 
viral dissemination, as the cell is carefully disassembled 
and cleared by the host’s immune system [50]. On the 
contrary, uncontrolled necrosis is unfavourable for the 
host, as this results in the release of cytoplasmic mate-
rial, including viral particles. In turn, these viral parti-
cles might spread in the host and infect new cells. Here, 
apoptosis, but not necrosis, was induced in up to 50% 
of the infected equine T and B lymphocytes. In com-
parison, EBV early proteins participate in the fragmen-
tation of chromosomal DNA and the onset of apoptosis 
during lytic infection of human lymphoblasts in  vitro 
[39]. However, the high MOI used in our and the latter 
experiment might have favoured the onset of apoptosis. 
Transcription and translation of a high number of viral 
DNA copies might have flooded the cellular endoplas-
mic reticulum with viral proteins destined for assembly. 
In turn, overload of the endoplasmic reticulum could 
have elicited a cascade of signal transduction pathways, 
eventually leading to apoptosis [50]. Indeed, it seems 
unlikely that a virus, so optimally adapted to its host, kills 
its host cell on purpose. On the contrary, multiple gam-
maherpesviruses (e.g. EBV, HHV8, BoHV4) have evolved 
mechanisms to induce latency and inhibit apoptosis to 
prolong their survival in the host [51–54]. For example 
in latently EBV-infected B lymphocytes, only a limited 
Figure 4 Induction of chromatin condensation and nuclear fragmentation in EHV5 antigen-expressing T lymphocytes (A) and B 
lymphocytes (B) following inoculation at a MOI of 10. Left panels; the percentage of EHV5-inoculated cells expressing both EHV5 antigens and 
nuclear fragmentation is indicated by black bars. White bars represent the percentage of inoculated cells that express EHV5 antigens, but show 
no signs of nuclear fragmentation. Data are represented as mean + SD and were obtained from 3 individual horses. Right panels; representative 
confocal images of EHV5 expression (Sultan; green) in T and B lymphocytes. Cell nuclei were counterstained with Hoechst 33342 (blue). Note the 
signs of nuclear fragmentation (i.e. translucent and/or compartmented appearance of cell nuclei, as shown by the translucent and/or punctuated 
Hoechst signal; white arrows). The scale bars represent 5 µm.
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number of viral-coded proteins are expressed, includ-
ing latent membrane protein 1 (LMP1). As this protein 
interacts with apoptotic signals, the virus cleverly guides 
the infected B lymphocyte towards a long-living (mem-
ory) state [55]. The establishment of EHV5 latency in 
equine T and B lymphocytes could further explain the 
drop of EHV5-positive cells starting from 24 and 72 hpi, 
respectively.
Although infected lymphocytes clearly produced viral 
proteins intracellularly, the extracellular virus titer did 
not increase throughout the course of the experiment. 
The low viral titers that were observed at all time points 
presumably reflect remnant inoculum  viral particles. 
In dying cells, viral proteins were contained through 
apoptosis. In live EHV5-infected cells, however, assem-
bly of virus particles and/or release of cell-free progeny 
virions into surroundings must have been hampered. 
Indeed, herpesvirus infections are commonly non-pro-
ductive in leukocytes and this strategy allows the virus 
to remain in its host, undetectable by the immune sys-
tem [31, 56, 57]. Still, we frequently observed clustering 
of EHV5-positive T or B lymphocytes, indicating that 
the virus may spread via cell–cell transfer. Cell-to-cell 
transfer is a well-known strategy used by herpesviruses 
to bypass the hostile immune environment of the host, 
containing phagocytes, antibodies and complement [58, 
59]. Indeed, previous studies demonstrated that the effi-
ciency of EBV transfer from B lymphocytes to epithelial 
cells was highly upregulated by cell–cell contact [58, 60]. 
Binding of EBV gp350 with the B lymphocyte surface 
protein CD21 was proposed to unmask other putative 
viral glycoproteins, essential for epithelial cell binding. 
To investigate whether EHV5 could also be transferred 
from lymphocytes to EREC, we co-cultured infected 
lymphocytes at the apical surface of naïve EREC. Still, 
EHV5 was unable to infect and replicate in EREC (data 
not shown). It would be interesting to assess viral transfer 
from lymphocytes to the basolateral surface of EREC, as 
it would be the case in  vivo. For example, EBV transfer 
infection of polarized epithelial cells is restricted to the 
basolateral surface, even though cell–cell contacts are 
also established at the apical surface [61]. The researchers 
suggested that putative EBV binding and entry receptors 
on the epithelial cells are similarly restricted to the baso-
lateral surface. Unfortunately, we could not perform this 
experiment due to technical limitations. The small pore 
size of the transwells, necessary for EREC support, did 
Figure 5 Induction of apoptosis in EHV5 antigen-expressing T lymphocytes (A) and B lymphocytes (B) following inoculation at a MOI of 
10 (72 hpi). Left panels; the percentage of mock- (black bars) or EHV5- (white bars) inoculated cells showing signs of apoptosis (left) or necrosis 
(right). Data are represented as means + SD and asterisks indicate significant differences (***P < 0.001) between mock- and EHV5-inoculated 
cells. Experiments were performed on cells from 3 individual horses. Cell death was analysed on living cells by the “Dead Cell Apoptosis Kit” from 
ThermoFisher Scientific. Apoptosis was characterized by the binding of annexin V to cellular phosphatidyl serine and necrosis was identified by 
binding of propidium iodide to nucleic acids in the cell. Right panels; after incubation with annexin V-FITC® (green), cells were fixed and stained for 
EHV5 antigens (Sultan; red). Cell nuclei are counterstained in blue. The scale bars represent 5 µm.
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not allow sufficient cell–cell contacts between the baso-
lateral surface of EREC and equine lymphocytes (data not 
shown).
In our study, EHV5 did not replicate in equine mono-
cytes in  vitro and in fibroblasts of ex  vivo mucosal 
explants. This is in contrast with a study from Williams 
et al. [22], who found viral antigens in the alveolar mac-
rophages and interstitial fibroblasts of the lungs in vivo. 
Differentiated macrophages are more specialized for 
phagocytosis than monocytes. Thus, the presence of viral 
antigens within alveolar macrophages of infected horses 
could merely be a consequence of phagocytosis. In addi-
tion, EHV5-positive fibroblasts were only found in a lim-
ited number of infected horses several weeks following 
initial challenge. In our short-living ex vivo explant sys-
tem, EHV5 might not have been able to infect fibroblasts.
Based on this work, we suggest the following hypothet-
ical model for EHV5 pathogenesis in the horse (Figure 6). 
Upon inhalation in a healthy horse, infectious EHV5 par-
ticles do not infect the ciliated respiratory epithelium, but 
are rather propelled by the mucociliary escalator towards 
the tonsillar crypts, embedded in the nasopharynx [62–
64]. Lymphocytes reside in lymphoid follicles, just under-
neath the squamous epithelium of tonsillar crypts. As 
this epithelium contains gaps throughout the crypt sur-
face, EHV5 possibly can directly access susceptible T and 
B lymphocytes. Following viral replication, virus particles 
are contained within these cells to protect them from the 
outer hostile environment. One part of these infected 
lymphocytes will eventually succumb due to apopto-
sis. The other part may be “saved” by EHV5 to function 
as a life-long latency reservoir. Via periodic reactivation, 
a latently infected horse will recurrently shed progeny 
virus to the outer world. Indeed, viral DNA is frequently 
recovered from PBMC and nasal secretions of healthy 
horses [9, 10, 23, 27]. How exactly the virus escapes from 
Figure 6 Hypothetical model of EHV5 pathogenesis in the horse. Drawings are based on SMART servier medical art templates. The horse’s 
respiratory tract is designated in blue, the circulatory system in red and the upper airway lymph nodes in orange. (1) EHV5 virions are propelled 
by the mucociliary escalator towards the tonsillar crypts, embedded in the nasopharynx. Here, EHV5 directly infects lymphocytes residing in 
lymphoid follicles (LF). Infected lymphocytes then transport the virus either directly to the bloodstream or via the lymph vessels and (2) the 
draining lymph nodes (especially the retropharyngeal lymph nodes) to the bloodstream. In the lymphoid follicles or draining lymph nodes, EHV5 
spreads to neighbouring lymphocytes via cell–cell transfer. EHV5-infected lymphocytes might either succumb due to apoptosis or survive and 
function as a life-long reservoir for EHV5. Via the bloodstream or via lymphocyte-homing, EHV5-infected lymphocytes (re)route to different parts 
of the respiratory tract, e.g. the nasal cavities or the trachea (3a) or the lungs (3b). (3a) EHV5-infected lymphocytes might transfer infection to 
epithelial cells, which could amplify the infection and shed a high viral load in respiratory secretions. (3b) EHV5 infects alveolar cells and spreads 
to neighbouring cells via cell–cell transfer. Viral replication, together with host-specific predisposing factors might eventually trigger the onset of 
fibrosis and EMPF due to yet unknown reasons.
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these lymphocytes to shed progeny virus in respiratory 
secretions is currently unknown. As for EBV, infected 
leukocytes might (re)route to the respiratory tract and 
produce virions lacking gp42 [58, 60]. These virus parti-
cles might then be transferred to epithelial cells, which 
could amplify the infection and shed a high viral load in 
respiratory secretions to infect new hosts. Finally, epithe-
lial cell-derived EHV5 particles are optimally designed, 
i.e. contain gp42, to infect lymphocytes. Regular patrol-
ling within the mucosa-associated lymphoid tissue 
(MALT) of latently-infected lymphocytes brings them 
to different sites of the respiratory mucosa, including the 
small bronchioli within the lungs. Here, free virus parti-
cles are able to infect alveolar cells and further spread to 
neighbouring cells using cell–cell transfer. Viral replica-
tion, together with host-specific predisposing factors (e.g. 
age and immunologic response) might eventually trigger 
the onset of fibrosis and EMPF [65]. Overall, our findings 
established the foundations for future research, which 
will eventually elucidate the mechanisms regulating 
EHV5 disease and triggering the development of EMPF.
Additional files
Additional file 1. Flow cytometric analysis of the equine T and B 
lymphocyte populations’ purity. Equine T and B lymphocytes were 
diluted in PBS, containing 10% negative goat serum and antibodies (1:20) 
for 1 h at 4 °C. Equine T and B lymphocytes were incubated with a mouse 
monoclonal anti-CD3 antibody (clone UC_F6G) or a mouse monoclonal 
anti-pan B lymphocyte antibody (clone CVS36), respectively. The mouse 
monoclonal anti-PCV2 antibody (A27) was used as isotype (IgG1) control 
antibody. After a centrifugation step, cells were incubated with a goat 
anti-mouse IgG  FITC®-conjugated antibody for 1 h at 4 °C. Finally, cells 
were analysed with a CytoFLEX flow cytometer (Beckman Coulter Life 
Sciences, Indianapolis, USA).
Additional file 2. Validation of the polyclonal horse anti-EHV5 anti-
body (Sultan). The biotinylated polyclonal horse anti-EHV5 antibody (Sul-
tan) recognizes EHV5 antigens in EHV5-infected RK13 cells 48 hpi in both 
immunofluorescence (A) and immunocytological staining (B) (left panels). 
The biotinylated polyclonal horse anti-EHV1 antibody was included as 
control antibody (right panels). The scale bars represent 50 μm.
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